专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140328836A1 HER2/neu-Specific Antibodies and Methods of Using Same 有权
标题翻译： HER2 / neu特异性抗体及其使用方法
公开(公告)号：US20140328836A1
公开(公告)日：2014-11-06
申请号：US14332239
申请日：2014-07-15
申请人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
发明人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
IPC分类号： C07K16/32 , A61K39/395 , A61K45/06
CPC分类号： C07K16/32 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/71 , C07K2317/732 , C07K2317/92
摘要： This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及与已知的4D5抗体相比具有降低的糖基化的HER2 / neu特异性结合HER2 / neu的嵌合4D5抗体的抗体。本发明还涉及将4D5抗体及其组合物用于诊断，预后和治疗疾病如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的方法。

2. 发明授权

US08802093B2 HER2/neu-specific antibodies and methods of using same 有权
标题翻译： HER2 / neu特异性抗体及其使用方法
公开(公告)号：US08802093B2
公开(公告)日：2014-08-12
申请号：US12933885
申请日：2009-03-25
申请人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
发明人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
IPC分类号： A61K39/395 , A61P35/04 , C07K16/28
CPC分类号： C07K16/32 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/71 , C07K2317/732 , C07K2317/92
摘要： This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及与已知的4D5抗体相比具有降低的糖基化的HER2 / neu特异性结合HER2 / neu的嵌合4D5抗体的抗体。本发明还涉及将4D5抗体及其组合物用于诊断，预后和治疗疾病如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的方法。

3. 发明申请

US20120276094A1 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same 有权
标题翻译：具有变异Fc区的抗体的鉴定和工程及其使用方法
公开(公告)号：US20120276094A1
公开(公告)日：2012-11-01
申请号：US13524652
申请日：2012-06-15
申请人： JEFFREY STAVENHAGEN , SERGEY GORLATOV , CHRISTOPHER RANKIN , NADINE TUAILLON
发明人： JEFFREY STAVENHAGEN , SERGEY GORLATOV , CHRISTOPHER RANKIN , NADINE TUAILLON
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： G01N33/574 , A61K2039/505 , C07K16/283 , C07K16/2887 , C07K16/32 , C07K16/44 , C07K2317/24 , C07K2317/52 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by FcγR is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
摘要翻译：本发明涉及包含变体Fc区的分子，其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区与FcγRIIIA和/或FcγRIIA以更大的亲和力相对于包含野生型Fc区的可比分子。本发明的分子可用于预防，治疗或改善与疾病，病症或感染相关的症状。本发明的分子特别可用于治疗或预防需要由FcγR介导的效应细胞功能增强的功效的疾病或病症，以及提高其作用由ADCC介导的治疗性抗体的治疗功效。

4. 发明授权

US08193318B2 FcγRIIB specific antibodies and methods of use thereof 有权
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：US08193318B2
公开(公告)日：2012-06-05
申请号：US12186058
申请日：2008-08-05
申请人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon , Ezio Bonvini
发明人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon , Ezio Bonvini
IPC分类号： C07K16/00 , C12P21/08 , C07K14/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K16/2896 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/732
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof for the treatment, prevention, management, or amelioration of a disease or disorder. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
摘要翻译：本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA特异性结合FcγRIIB的抗体或其片段。本发明还包括抗FcγRIIB抗体或其抗原结合片段用于治疗，预防，治疗或改善疾病或病症的用途。本发明还提供了通过施用本发明的抗体来增强治疗性抗体的效应子功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过用疫苗组合物施用本发明的抗体来增强疫苗组合物的功效的方法。本发明还提供了通过施用本发明的抗原 - 抗体复合物和抗体来破坏对抗原的耐受性的方法。

5. 发明申请

US20110152504A1 CD16A Binding Proteins and Use for the Treatment of Immune Disorders 审中-公开
标题翻译： CD16A结合蛋白和用于治疗免疫疾病的用途
公开(公告)号：US20110152504A1
公开(公告)日：2011-06-23
申请号：US12904554
申请日：2010-10-14
申请人： Leslie S. Johnson , Ling Huang , Hua Li , Nadine Tuaillon
发明人： Leslie S. Johnson , Ling Huang , Hua Li , Nadine Tuaillon
IPC分类号： C07K16/28
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： CD 16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.
摘要翻译： CD 16A结合蛋白可用于减少有害免疫反应。在一个方面，任选缺乏效应子功能的人源化抗-CD16A抗体用于治疗免疫疾病如特发性血小板减少性紫癜和自身免疫性溶血性贫血。

6. 发明申请

US20100196372A1 FcgammaRIIB Fusion Proteins and Compositions Thereof 审中-公开
标题翻译： FcgammaRIIB融合蛋白及其组合
公开(公告)号：US20100196372A1
公开(公告)日：2010-08-05
申请号：US12721887
申请日：2010-03-11
申请人： Leslie S. Johnson , Hua Li , Nadine Tuaillon
发明人： Leslie S. Johnson , Hua Li , Nadine Tuaillon
IPC分类号： A61K39/395 , A61P37/00
CPC分类号： C07K16/283 , A61K39/39541 , A61K2039/505 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2319/30 , C07K2319/32 , A61K2300/00
摘要： The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.
摘要翻译：本发明涉及分子，优选可溶性（即非膜结合的）多肽，最优选包含FcγR的细胞外可溶性区域，其衍生物和类似物以及编码它们的核酸的可溶性融合多肽。本发明的分子特别可用于治疗，治疗或预防或改善自身免疫疾病的一种或多种症状，特别是用于改善与免疫性血小板减少性紫癜相关的血小板缺乏症。本发明提供了通过施用本发明的分子来增强用于自身免疫疾病的标准，当前或实验疗法的治疗功效的方法和组合物。

7. 发明申请

US20070036786A1 Method of treating autoimmune disease using humanized anti-CD16A antibodies 审中-公开
标题翻译：使用人源化抗CD16A抗体治疗自身免疫性疾病的方法
公开(公告)号：US20070036786A1
公开(公告)日：2007-02-15
申请号：US11485556
申请日：2006-07-11
申请人： Nadine Tuaillon , Leslie Johnson , Ezio Bonvini , Kathryn Stein
发明人： Nadine Tuaillon , Leslie Johnson , Ezio Bonvini , Kathryn Stein
IPC分类号： A61K39/395
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/76
摘要： CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.
摘要翻译：描述了可用于减少有害免疫反应的CD16A结合蛋白。一方面，任选缺乏效应子功能的人源化抗CD16A抗体用于治疗免疫疾病，例如特发性血小板减少性紫癜和自身免疫性溶血性贫血。

8. 发明申请

US20050260213A1 Fcgamma-RIIB-specific antibodies and methods of use thereof 审中-公开
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：US20050260213A1
公开(公告)日：2005-11-24
申请号：US11108135
申请日：2005-04-15
申请人： Scott Koenig , Maria Veri , Nadine Tuaillon , Ezio Bonvini , Jeffrey Stavenhagen , Christopher Rankin
发明人： Scott Koenig , Maria Veri , Nadine Tuaillon , Ezio Bonvini , Jeffrey Stavenhagen , Christopher Rankin
IPC分类号： A61K39/395 , C07K16/28 , C07K16/46
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为单一药物治疗用于治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

9. 发明授权

US08946387B2 FcγRIIB specific antibodies and methods of use thereof 有权
公开(公告)号：US08946387B2
公开(公告)日：2015-02-03
申请号：US12186065
申请日：2008-08-05
申请人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon , Ezio Bonvini
发明人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon , Ezio Bonvini
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/40 , C07K16/28 , C07K16/32 , A61K39/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K16/32 , C07K2317/34 , C07K2317/41 , C07K2317/71 , C07K2317/732 , C07K2317/76
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

10. 发明授权

US08697071B2 Identification and engineering of antibodies with variant Fc regions and methods of using same 有权
标题翻译：具有变体Fc区的抗体的鉴定和工程及其使用方法
公开(公告)号：US08697071B2
公开(公告)日：2014-04-15
申请号：US13524652
申请日：2012-06-15
申请人： Jeffrey Stavenhagen , Sergey Gorlatov , Christopher Rankin , Nadine Tuaillon
发明人： Jeffrey Stavenhagen , Sergey Gorlatov , Christopher Rankin , Nadine Tuaillon
IPC分类号： A61K39/395 , A61K39/40 , A61K39/42 , C07K16/00
CPC分类号： G01N33/574 , A61K2039/505 , C07K16/283 , C07K16/2887 , C07K16/32 , C07K16/44 , C07K2317/24 , C07K2317/52 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by FcγR is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
摘要翻译：本发明涉及包含变体Fc区的分子，其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区与FcγRIIIA和/或FcγRIIA以更大的亲和力相对于包含野生型Fc区的可比分子。本发明的分子可用于预防，治疗或改善与疾病，病症或感染相关的症状。本发明的分子特别可用于治疗或预防需要由FcγR介导的效应细胞功能增强的功效的疾病或病症，以及提高其作用由ADCC介导的治疗性抗体的治疗功效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式